I-MED Pharma to Bring Clinically Proven E>Eye IRPL® Technology to Canada
MONTREAL, May 24, 2018 (GLOBE NEWSWIRE) -- I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and management, is pleased to announce the signing of a Canadian distribution agreement with ESW Vision for the patented E>Eye device.
|
|||||
E>Eye, designed and manufactured in France by E-Swin, is the first and only CE certified medical device in the world using patented IRPL® technology developed specifically for the treatment of dry eye disease caused by meibomian gland dysfunction (MGD), the leading cause of evaporative dry eye disease.
This new type of polychromatic pulsed light produces perfectly calibrated and homogeneously sequenced “cold light” pulses which safely stimulate the meibomian glands to resume secretions, restoring the lacrimal film, thus improving symptoms associated with ocular dryness.
- Clinically proven
- Quick, painless and non-invasive
- Fast, effective results
- Affordable
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/f7a5554f-e6e9-4d73-9597-71d0a35eb64e
Daniel Hofmann, President of I-MED Pharma stated, E-Swin is a global leader in ocular IPL laser technology and has garnered huge interest in the industry with the success of the E>Eye device in providing effective, long-term results with symptoms associated with evaporative dry eye caused by MGD. We are thrilled to partner with ESW Vision to add this industry leading device to our dry eye product portfolio. We are confident that Canadian ophthalmologists and optometrists will be enthusiastic to incorporate the E>Eye System into their dry eye practices.”
I-MED Pharma Inc. is a privately held Canadian company, headquartered in Montreal, Quebec, servicing Canadian ophthalmologists, optometrists and the global eye care community. Established almost thirty years ago, I-MED Pharma creates and distributes innovative medical, surgical and veterinary eye care products worldwide. It continually researches, develops and sources the most effective and advanced solutions to eye disorders like cataracts, corneal degeneration, dry eye, glaucoma and Meibomian gland disease.
I-MED Pharma is proud to have been at the forefront of treating Dry Eye Syndrome as a serious disease and invests heavily into education and developing effective dry eye products. I-MED Pharma’s ocular surface disease product range includes diagnostic tools, ocular hygiene, nutrition, dry eye drops, and therapeutic accessories.
For more information, please email media@imedpharma.com or visit imedpharma.com.
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
